Barigen 4 mg (Baricitinib) tablets are an oral, targeted anti-inflammatory therapy used in the management of moderate-to-severe rheumatoid arthritis and other immune-mediated conditions. As a Bangladesh-based exporter, Orio Pharma supplies Barigen and related baricitinib brands to hospitals, tender agents, and licensed pharmaceutical distributors across Saudi Arabia, where demand for high-quality Janus kinase (JAK) inhibitor therapy continues to grow.

This guide is written for procurement teams, pharmacists, and healthcare professionals who need a clear, regulatory-grounded overview of baricitinib: what it is, its approved indications, how it works, the strengths and brands available for supply, its safety profile, and how to arrange reliable B2B sourcing into the Saudi market under SFDA requirements.

What Is Barigen 4 mg (Baricitinib)?

Barigen 4 mg is a film-coated tablet containing the active ingredient baricitinib, a small-molecule Janus kinase (JAK) inhibitor. Baricitinib is the same molecule marketed internationally under the originator brand Olumiant, first approved by the U.S. Food and Drug Administration (FDA) in 2018. It belongs to the broader class of targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs) and acts as an oral immunomodulator rather than an injectable biologic.

Because it is taken orally as a once-daily tablet, baricitinib offers a convenient alternative to injectable biologic therapies for suitable patients. It may be used alone or in combination with methotrexate, depending on the treating physician’s assessment. Barigen is manufactured to strict pharmaceutical quality standards in Bangladesh and is offered for export supply through licensed channels.

Approved Indications

Baricitinib carries several approved indications across major regulatory agencies. The scope of approval differs slightly between the FDA and the European Medicines Agency (EMA), and any use in Saudi Arabia must follow the locally registered label and SFDA guidance. Based on official prescribing information, approved and label-supported uses include:

• Moderate-to-severe active rheumatoid arthritis in adults. Under the FDA label, baricitinib is indicated for patients who have had an inadequate response to one or more tumor necrosis factor (TNF) blockers; the EMA label covers adults with an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs).
• Severe alopecia areata in adults. Baricitinib was the first systemic medicine approved by the FDA for severe alopecia areata, an autoimmune form of hair loss.
• COVID-19 in hospitalized adults. The FDA label indicates baricitinib for the treatment of coronavirus disease 2019 (COVID-19) in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

The EMA has additionally authorised baricitinib for moderate-to-severe atopic dermatitis and, in specified populations, alopecia areata and juvenile idiopathic arthritis. Registered indications, patient age ranges, and treatment settings vary by jurisdiction, so prescribers and procurement teams should always defer to the SFDA-registered prescribing information applicable in Saudi Arabia. Baricitinib is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressants such as azathioprine and cyclosporine.

Mechanism of Action: JAK1/JAK2 Inhibition

Baricitinib is a selective and reversible inhibitor of Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2). Janus kinases are intracellular enzymes that transmit signals arising from cytokine and growth-factor receptors on the cell surface. When these signalling molecules bind their receptors, JAK enzymes activate signal transducers and activators of transcription (STATs), which then move into the cell nucleus and switch on genes that drive inflammation and immune-cell activity.

By blocking JAK1 and JAK2 within this JAK-STAT signalling pathway, baricitinib reduces the phosphorylation and activation of STAT proteins. This dampens the production and signalling of pro-inflammatory cytokines that are central to autoimmune conditions such as rheumatoid arthritis. In practical clinical terms, this translates into reduced joint inflammation, less pain and swelling, and slowed progression of the structural joint damage associated with chronic inflammatory disease. The same immunomodulatory action underlies its use in other immune-driven conditions.

Available Strengths & Brands

Orio Pharma supplies baricitinib as film-coated oral tablets in 2 mg and 4 mg strengths. Barigen 4 mg is the primary brand featured here, and several additional Bangladeshi-manufactured baricitinib brands are available to support flexible sourcing and formulary preferences. Available brands and strengths include:

• Barigen — 4 mg tablets (General Pharmaceuticals Ltd.)
• Barinib — 2 mg tablets (Drug International Ltd.)
• Baricent — 2 mg tablets (Incepta Pharmaceuticals Ltd.)
• Baricinix — 2 mg and 4 mg tablets (Beacon Pharmaceuticals Ltd.)

The availability of both 2 mg and 4 mg strengths across these brands allows treating physicians to individualise therapy and adjust as clinically appropriate. Note that this article describes available strengths only; dosing schedules, titration, and administration must be determined solely by the prescribing physician in line with the approved label. For current stock, pack sizes, and export documentation, contact our team.

Safety Profile: Side Effects & Key Adverse Reactions

Like all JAK inhibitors, baricitinib requires careful patient selection and ongoing medical monitoring. The following summary is drawn from the official FDA and EMA prescribing information and is provided for educational purposes; it does not replace the full label or the clinical judgement of a qualified prescriber.

Common Adverse Reactions

The most commonly reported adverse reactions with baricitinib include:

• Upper respiratory tract infections
• Headache
• Nausea
• Neutropenia (reduced neutrophil count)
• Increased risk of serious infection, including pneumonia
• Elevated liver enzymes (raised transaminases)
• Increased cholesterol levels (hyperlipidaemia)
• Herpes zoster (shingles)
• Urinary tract infections, acne, folliculitis, and increases in creatine phosphokinase

Serious Warnings (JAK-Inhibitor Class)

The FDA-approved labeling for baricitinib carries a Boxed Warning reflecting risks recognised across the JAK-inhibitor class. Procurement teams and clinicians should be aware of these themes:

• Serious infections — including bacterial, fungal, viral, and opportunistic infections such as tuberculosis; some cases have led to hospitalisation or death.
• Mortality — a higher rate of all-cause mortality has been observed with JAK inhibitors in certain patient populations compared with alternative therapies.
• Malignancy — an increased risk of certain cancers, including lymphoma, has been reported.
• Major adverse cardiovascular events (MACE) — including cardiovascular death, myocardial infarction, and stroke.
• Thrombosis — including deep vein thrombosis, pulmonary embolism, and arterial thrombosis, some events being serious and occasionally fatal.

Gastrointestinal perforation, laboratory abnormalities (such as changes in neutrophil and lymphocyte counts, haemoglobin, and lipids), and reactivation of viral infections are further considerations. Baseline and periodic monitoring, tuberculosis screening, and appropriate immunisation before initiation are recommended per the label. Any unusual or persistent symptoms should be reported to a healthcare provider without delay.

Regulatory Status (FDA / EMA / SFDA)

Baricitinib is a globally recognised molecule with a well-documented regulatory history:

• FDA (United States): First approved in 2018 for rheumatoid arthritis, with subsequent approvals for COVID-19 in hospitalized adults and for severe alopecia areata. The U.S. label includes a Boxed Warning for serious infections, mortality, malignancy, MACE, and thrombosis.
• EMA (European Union): Authorised for moderate-to-severe rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and juvenile idiopathic arthritis in specified populations, classified as an immunosuppressant JAK inhibitor.
• SFDA (Saudi Arabia): Baricitinib products supplied into Saudi Arabia must comply with Saudi Food and Drug Authority registration and import requirements. Local registration status, the approved indications, and the applicable prescribing information govern clinical use within the Kingdom.

Orio Pharma works with licensed importers and distributors to help ensure that documentation aligns with SFDA expectations for regulated pharmaceutical imports.

Sourcing Barigen & Baricitinib: B2B Supply to Saudi Arabia

As a Bangladesh-based pharmaceutical exporter, Orio Pharma supplies Barigen and other baricitinib brands to hospitals, oncology and rheumatology centres, tender agents, and licensed distributors serving the Saudi market. Our B2B model is built around reliability, documentation, and quality:

• Consistent supply of 2 mg and 4 mg tablet strengths across multiple brands to support formulary flexibility.
• Quality-assured manufacturing in Bangladesh to recognised pharmaceutical standards.
• Export documentation support to facilitate compliant import into Saudi Arabia under SFDA requirements.
• Volume-based supply for institutional, tender, and wholesale requirements.

Pricing is not published on this platform. For current availability, pack configurations, lead times, and a formal quotation, please contact our team for current pricing and supply terms.

Frequently Asked Questions

Q: What is Barigen 4 mg used for?
A: Barigen 4 mg contains baricitinib, a JAK1/JAK2 inhibitor used mainly for moderate-to-severe rheumatoid arthritis. Depending on the applicable label, baricitinib is also approved for severe alopecia areata and, per the FDA label, for COVID-19 in hospitalized adults requiring oxygen support. Use must follow the SFDA-registered indications.

Q: What strengths and brands of baricitinib are available?
A: Baricitinib is available as film-coated tablets in 2 mg and 4 mg strengths. Available brands include Barigen (4 mg), Barinib (2 mg), Baricent (2 mg), and Baricinix (2 mg and 4 mg).

Q: Is baricitinib a biologic?
A: No. Baricitinib is an oral, small-molecule targeted synthetic DMARD (a JAK inhibitor), not an injectable biologic. It can be used alone or in combination with methotrexate as directed by a physician.

Q: What are the main safety warnings for baricitinib?
A: The FDA label carries a Boxed Warning covering serious infections, increased mortality, malignancy, major adverse cardiovascular events (MACE), and thrombosis. Patients require screening, monitoring, and specialist supervision throughout treatment.

Q: How can hospitals or distributors in Saudi Arabia order Barigen?
A: Licensed hospitals, tender agents, and distributors can contact the Orio Pharma team directly to discuss availability, documentation, and SFDA-compliant supply. Pricing is provided on inquiry based on volume and delivery requirements.

Q: Is a prescription required?
A: Yes. Baricitinib is a prescription-only medicine and must be prescribed, dispensed, and monitored by qualified healthcare professionals in accordance with local regulations.

Key Takeaways

• Barigen 4 mg contains baricitinib, an oral JAK1/JAK2 inhibitor used primarily for moderate-to-severe rheumatoid arthritis, first FDA-approved in 2018.
• Label-supported indications also include severe alopecia areata and, per the FDA label, COVID-19 in hospitalized adults requiring oxygen support.
• It works by inhibiting the JAK-STAT signalling pathway to reduce inflammatory cytokine activity.
• Available as 2 mg and 4 mg tablets across brands including Barigen, Barinib, Baricent, and Baricinix.
• The JAK-inhibitor class carries a Boxed Warning: serious infections, mortality, malignancy, MACE, and thrombosis.
• Orio Pharma supplies SFDA-compliant baricitinib to hospitals and distributors across Saudi Arabia — contact our team for current pricing.

References

1. U.S. Food and Drug Administration (FDA). OLUMIANT (baricitinib) tablets — Highlights of Prescribing Information. Available at: https://pi.lilly.com/us/olumiant-uspi.pdf
2. U.S. FDA / DailyMed. OLUMIANT- baricitinib tablet, film coated — Label. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=866e9f35-9035-4581-a4b1-75a621ab55cf
3. European Medicines Agency (EMA). Olumiant (baricitinib) — European Public Assessment Report (EPAR). Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/olumiant
4. Saudi Food and Drug Authority (SFDA). Drug registration and prescribing information. Available at: https://www.sfda.gov.sa/en

Physician Consultation

Always consult a qualified doctor, physician, or healthcare professional before initiating, changing, or discontinuing baricitinib therapy. Individual suitability, screening, dosing, and monitoring must be determined by the treating physician in line with the approved prescribing information.

Legal & Medical Disclaimer: This content is provided for general informational and business-to-business procurement purposes only and does not constitute medical advice, a treatment recommendation, or an offer to sell a prescription medicine to the general public. Baricitinib is a prescription-only medicine that must be prescribed and supervised by a licensed healthcare professional. Approved indications, safety information, and availability vary by country and are governed by the relevant regulatory authority, including the SFDA in Saudi Arabia. Orio Pharma makes no representation that any product is registered or available in a specific jurisdiction. Medical statements herein are drawn from official FDA and EMA sources cited above.

Source Barigen & Baricitinib for Saudi Arabia: Orio Pharma is a trusted Bangladesh-based exporter supplying quality-assured baricitinib tablets to licensed hospitals, tender agents, and distributors across Saudi Arabia. For current availability, documentation, and pricing, contact our team today.